A Multi-Center, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Study to Evaluate the Safety and Efficacy of Huperzine A Sustained-Release Tablets in Patients With Mild to Moderate Alzheimer's Disease

NCT01282619 Phase 2/Phase 3 UNKNOWN

The main purpose of this study is to evaluate the safety and efficacy of Huperzine A sustained release tablets in patients with mild to moderate Alzheimer's Disease.

Details

Lead sponsor	Shandong Luye Pharmaceutical Co., Ltd.
Phase	Phase 2/Phase 3
Status	UNKNOWN
Enrolment	390
Start date	2010-05
Completion	2012-06

Conditions

• Alzheimer's Disease

Interventions

• Huperzine A
• huperzine A
• Placebo

Primary outcomes

• Alzheimer's Disease Assessment Scale - Cognitive Subscale — week 24

Countries

China